What does this research mean for the field?

Resistance to EGFR-targeted therapies in non-small cell lung cancer is driven by an adaptive SOS response in drug-tolerant persister cells, which induces mutagenesis and complex genomic aberrations. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To delineate the molecular mechanisms driving EGFR inhibitor resistance in non-small cell lung cancer, focusing on drug-tolerant persister cells and treatment-induced mutagenesis.

August 29, 2026

Targeting EGFR in lung cancer: lessons in signal transduction and treatment-induced mutagenesis.

View Full Paper

Ask AI

Bookmark

Authors

ASArturo Simoni-NievesUniversidad Autónoma Metropolitana MDMarieke Van DaeleWeizmann Institute of Science HKHarrison B. KonskerBoca Raton Regional Hospital

Discussion

Member takes

Implication

Review reveals mechanisms of treatment-induced mutagenesis and drug tolerance in EGFR-mutant lung cancer, highlighting novel therapeutic strategies to overcome resistance.

Key Points

To delineate the molecular mechanisms driving EGFR inhibitor resistance in non-small cell lung cancer, focusing on drug-tolerant persister cells and treatment-induced mutagenesis.
Synthesized molecular and clinical evidence regarding EGFR signaling, secondary resistance pathways, and histological transformation in non-small cell lung cancer.
Evaluated the cellular SOS survival response, oxidative DNA damage, and error-prone repair mechanisms associated with tyrosine kinase inhibitor therapy.
Targeted EGFR inhibition triggers an adaptive SOS-like survival mechanism in drug-tolerant persister cells, characterized by elevated reactive oxygen species and defective DNA repair.
Treatment-induced genomic instability leads to chromothripsis-like events, extrachromosomal circular DNA formation, gene fusions, and point mutations conferring permanent drug resistance.
Emerging therapeutic modalities—including fourth-generation tyrosine kinase inhibitors, allosteric inhibitors, targeted degraders, and bispecific antibodies—show promise in circumventing acquired resistance.

Cite This Study

Simoni-Nieves et al. (2026) studied this question.

synapsesocial.com/papers/6a9299bb8e5d7d1fc0c11e6b https://doi.org/10.1098/rstb.2024.0512

View Full Paper

Ask AI

Bookmark

Implication

Review reveals mechanisms of treatment-induced mutagenesis and drug tolerance in EGFR-mutant lung cancer, highlighting novel therapeutic strategies to overcome resistance.

Targeting EGFR in lung cancer: lessons in signal transduction and treatment-induced mutagenesis.

Discussion

Member takes

Implication

Key Points

Cite This Study

Targeting EGFR in lung cancer: lessons in signal transduction and treatment-induced mutagenesis.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider